BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hemophilia Alliance
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251106T130000
DTEND;TZID=America/New_York:20251106T140000
DTSTAMP:20260423T050858
CREATED:20251027T141549Z
LAST-MODIFIED:20251030T171821Z
UID:71702-1762434000-1762437600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Bayer - Jivi - With Them as They Grow™ Clinical Study Data for Children 7 to 11 Yrs
DESCRIPTION:Date: Thursday\, November 6th\, 2025\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n  \n  \n \nWEBINAR TOPIC: \nJivi — With Them as They Grow™ Clinical Study Data for Children 7 to 11 Years. \nOBJECTIVE: \nThis session provides a clinical review of safety and efficacy data drawn from both the PROTECT Kids and Alfa-PROTECT studies. Data from these studies have been combined\, as each included participants aged 7 to less than 12 years. The studies were conducted to evaluate the safety and clinical effectiveness of Jivi in previously treated individuals within this age group who have severe hemophilia A. Get the latest data and learn how Jivi may fit the needs of your patients starting at age 7. \nIndications: JIVI ® is a recombinant DNA-derived\, Factor VIII concentrate indicated for use in previously treated adults and pediatric patients 7 years of age and older with hemophilia A (congenital Factor VIII deficiency) for: \n\nOn-demand treatment and control of bleeding episodes.\nPerioperative management of bleeding.\nRoutine prophylaxis to reduce the frequency of bleeding episodes.\n\n  \nLimitations of use JIVI is not indicated for use in: \n\nChildren less than 7 years of age due to a greater risk for hypersensitivity reactions and/or loss of efficacy.\nPreviously untreated patients (PUPs).\nTreatment of von Willebrand disease.\n\nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nDr. Akshat Jain MD\, MPH \nDirector of Sickle Cell Center of Excellence; Faculty Clinical Medicine and Pediatrics; Hematology Oncology and Cell Therapy; Loma Linda University School of Medicine
URL:https://hemoalliance.org/alliance-events/a-webinar-from-bayer-jivi-with-them-as-they-growclinical-study-data-for-children-7-to-11-yrs/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR